Clinical Trials Browser

Phase 1 × Lymphoma, Non-Hodgkin × Vincristine × Clear all

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT03467373 2025-01-17

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Phase 1 Completed

111 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02257242 2023-02-09

BRiM

Phase 1 Completed

11 enrolled 20 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03036904 2022-08-24

V+DA-EPOCH-R

Phase 1 Completed

31 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00000689 2021-11-02

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Phase 1 Completed

18 enrolled

Lymphoid

Acquired Immunodeficiency Syndrome, Lymphoma, Non-Hodgkin, Nervous System Neoplasms, HIV Infections

NCT00323323 2017-01-20

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

Phase 1 Completed

24 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT00901069 2016-10-17

Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma

Phase 1 Completed

12 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT00003166 2013-01-11

Bryostatin and Vincristine in B-Cell Malignancies

Phase 1 Completed

18 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00080925 2012-03-08

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Phase 1 Completed

20 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Clinical Trials

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

BRiM

V+DA-EPOCH-R

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma

Bryostatin and Vincristine in B-Cell Malignancies

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies